Paradigm Stock
HealthTechLooking to sell Paradigm stock or options?
Paradigm operates a health technology platform designed to support the clinical research ecosystem. The platform's purpose is to enhance the efficiency of clinical trials by connecting biopharmaceutical trial sponsors with healthcare providers and streamlining the process for patients. Paradigm aims to improve the healthcare sector by increasing trial efficiency, lowering participation barriers for healthcare providers, and accelerating the delivery of potentially life-saving treatments to patients.
Investors Include:
Mubadala Capital, BrightEdge, General Catalyst, ARCH Venture Partners, Magnetic Ventures, AIM13 CV Partners, GV, Lux Capital, American Cancer Society, F-Prime Capital, Rsquared.